Patient Education Blog

Posts Tagged ‘NEJM’

Blood Clots After Delivery – How Long is a Woman at Risk?

| Women and blood clots | Comments Off on Blood Clots After Delivery – How Long is a Woman at Risk?

Stephan Moll, MD writes… Women are at increased risk for blood clots (DVT, PE, stroke and heart attacks) during pregnancy and in the weeks after delivery.  If the risk is high enough, then preventive blood thinners (anticoagulants) are recommended, such as in a woman with a history of a previous blood clot. Guidelines exist as to which woman should be considered for blood thinners (ACOG 2012 guideline; ref 1).

The period after delivery is a particularly high-risk period for forming blood clots. It has typically been defined as being the 6 weeks after giving birth.  Therefore, if blood thinners are chosen after delivery, they are classically given for 6 weeks.  A study recently published in the New England Journal of Medicine (ref 2) examined whether the risk for blood clots is increased only for 6 weeks postpartum or whether the risk persists beyond the first 6 weeks. Read the rest of this entry »

The 4th New Oral Anticoagulant (Edoxaban): New Publication

| Blood thinners (anticoagulants), Eliquis - Apixaban, Pradaxa - dabigatran, Savaysa - Edoxaban, Therapy, Xarelto - Rivaroxaban | Comments Off on The 4th New Oral Anticoagulant (Edoxaban): New Publication

Stephan Moll, MD writes…  This week (Sept 1st 2013) the New England Journal of Medicine published the phase 3 clinical trial of the new oral blood thinner edoxaban compared with warfarin in the treatment of DVT and PE [ref 1].  It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

Drug Background

  • Edoxaban is one of the new oral blood thinners (anti-Xa anticoagulant) that does not require routine m0nitoring for its blood thinning effect and does not interact with vitamin K in the diet like warfarin.
  • At this point it is not FDA approved for any indication.
  • It is dosed once daily.
  • It reaches its peak blood thinning effect within 1 to 2 hours of oral intake.
  • Its half-life is 9-11 hours, which means that it is mostly out of the system in 48 hours after stopping it.
  • 35 % of the drug is cleared by the kidney, which means that it needs to be dose reduced or avoided in patients with significant impairment of kidney disease.

 

Methods

  • This is a randomized, double-blind study.
  • All patients received initial therapy with open-label enoxaparin into the skin (subcutaneous) or intravenous heparin for at least 5 days, before edoxaban or warfarin were started.
  • Edoxaban was dosed 60 mg once daily.  The dose was reduced to 30 mg once daily in patients with impaired kidney function  or a body weight less than 60 kg (132 pounds).
  • Length of treatment with blood thinners was 3 to 12 months.

 

Results

  • A total of 8292 patients were enrolled (4143 into the edoxaban treatment arm, 4149 into the warfarin arm).
  • Recurrent DVT or PE occured in  3.2 % of patients  in the edoxaban group and 3.5 % in the warfarin group. Conclusion: edoxaban is not worse than warfarin.
  • “Clinically relevant bleeding” occured in 8.5 % of patients in the edoxaban group and 10.3 % in the warfarin group.  Conclusion: edoxaban is better than warfarin from a bleeding point of view.
  • “Major bleeding” was the same in both groups, 1.4 % in the edoxaban group, 1.6 % in the warfarin group.  Conclusion: edoxaban is not worse than warfarin in respect to major bleeding.

 

Conclusions

The study concludes that edoxaban (a) is as effective as high quality standard therapy with warfarin, and (b) causes less clinically relevant bleeding.

 

My perspective – Edoxaban compared to the other new oral blood thinners

  • This table lists the key differences of the 4 new oral blood thinners in the treatment of VTE.
  • Edoxaban is the 4th of the big new oral blood thinners.  Its development lags behind the other 3 drugs, which are, at least for the irregular heart beat (atrial fibrillation) indication, already FDA-approved and on the market.  For DVT and PE treatment, only rivaroxaban (Xarelto) is FDA-approved; Xarelto is, therefore, the only one of the new oral blood thinners I would use at this time for DVT and PE treatment.
  • The main downside of the edoxaban study design is that edoxaban was not started right off the bat once the diagnosis of VTE was made in a patient, but that patients were first treated for at least 5 days with la ow molecular weight heparin (LMWH) blood thinner into the skin or i.v. heparin before edoxaban or warfarin were started.  This is similar to the dabigatran study design. The Xarelto and Pradaxa studies, on the other hand, gave the new oral blood thinner immediately after diagnosis, without the need for initial LMWH.  Thus, from a clinical-practical point of view, treatment of an acute DT or PE with edoxaban would be more cumbersome (cost of LMWH; teaching of self injections) than treatment with Xarelto or Eliquis.
  • Edoxaban is given once daily.  This is more convenient for patients than a twice daily regimen, such as with Pradaxa and Eliquis.
  • It is good to see data of DVT and PE trials on these various drugs published and the drugs making their way through the FDA approval process and, hopefully, eventually onto the market.  It is good to see data on a variety of different patients treated with these drugs, as there are a number of different types of patients which we need to learn more about as to how they fare on the new oral blood thinners: patients who are obese, have kidney impairment, have large PEs, have cancer, etc.  The data published in today’s New England Journal of Medicine are a very helpful addition to our knowledge-base.

 

References

  1. HOKUSAI-Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;Sept 1.
  2. Agnelli G et al. Oral Apixaban for the Treatment of acute venous thromboembolism. N Engl J Med, 369:799-808.
  3. The Einstein Investigators: Oral Rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 2010;363:2499-510.
  4. The Einstein Investigators: Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med 2012;366:1287-97.
  5. Schulman s et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52.

 

Disclosure: I have consulted for Janssen, Boehringer-Ingelheim and Daiichi.

 

Last updated: Sept 2nd, 2013